Glaucoma News and Research

Latest Glaucoma News and Research

Fifty patients to receive complimentary cataract surgery from Kremer Eye Center

A team from Kremer Eye Center is traveling to Belize City, Belize to provide essential eye care June 18-25, 2011. Fifty patients will receive complimentary cataract surgery.

17 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

Kowa presents three K-115 study results against glaucoma at ARVO 2011

Kowa Company Ltd, today announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension.

10 May 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that data from a clinical study of PRM-151 will be presented at the 2011 American Thoracic Society International Conference, being held May 13-18, 2011 in Denver, CO.

5 May 2011

Paulig Eye Surgery Center provides non-invasive alternative to keratoconus patients

The Paulig Eye Surgery Centre announces today that it has acquired advanced technology for performing Keraflex KXL, a new, non-invasive, non-surgical treatment for keratoconus. Surgeons at the Paulig Eye Surgery Centre will immediately begin treating patients using Avedro, Inc's Keraflex and KXL Systems.

3 May 2011

Scientists discover new gene underlying angle-closure glaucoma

Jackson Laboratory researchers and their collaborators have reported their discovery of a gene implicated in an acute and severe form of glaucoma known as angle-closure glaucoma.

3 May 2011

Merck's Phase III study shows efficacy results of tafluprost to treat ocular hypertension

Merck, known as MSD outside the United States and Canada, announced today that new Phase III data showed that patients with open-angle glaucoma or ocular hypertension, who were dosed once-daily with tafluprost, Merck's investigational, preservative-free prostaglandin analogue ophthalmic solution, experienced a reduction in intraocular pressure comparable to patients taking twice-daily preservative-free timolol maleate, a beta-adrenergic antagonist.

3 May 2011

ARVO announces 2011 award recipients in retinal research

The Association for Research in Vision and Ophthalmology is pleased to announce its 2011 ARVO Award recipients. These award recipients will be acknowledged at the ARVO 2011 Annual Meeting, May 1 - 5, in Fort Lauderdale, Fla.

2 May 2011

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Eli Lilly Canada announced today that Health Canada has approved Cymbalta for the management of chronic low back pain.

30 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

Researchers report game-changing advance in stem cell science

In a paper published in the April 25 early online edition of the Proceedings of the National Academy of Sciences, researchers at the University of California, San Diego School of Medicine, the Gladstone Institutes in San Francisco and colleagues report a game-changing advance in stem cell science: the creation of long-term, self-renewing, primitive neural precursor cells from human embryonic stem cells that can be directed to become many types of neuron without increased risk of tumor formation.

26 Apr 2011

UH honors glaucoma researcher with overall career excellence award

One of the world's foremost glaucoma researchers, Ronald S. Harwerth, is the recipient of the 2011 Esther Farfel Award, the highest distinction bestowed upon faculty by the University of Houston.

25 Apr 2011

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.

22 Apr 2011

Ortho-McNeil Neurologics announces voluntary recall of TOPAMAX 100mg Tablets

Ortho-McNeil Neurologics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., today announced it is voluntarily recalling two lots of TOPAMAX® (topiramate) 100mg Tablets. These two lots were shipped between 10/19/2010 and 12/28/2010 and distributed in the U.S. and Puerto Rico.

15 Apr 2011

Study: Patients with glaucoma experience psychological problems

Fear of the unknown is one of the greatest issues facing patients with glaucoma - the second leading cause of blindness worldwide after cataracts - according to research in the April issue of the Journal of Advanced Nursing. People also worry about how the eye disease, which can be hereditary, will affect other members of their family.

11 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

Optometrists congratulate Ontario government for progressive health policy

Ontarians will enjoy better access to eye health care now that optometrists can prescribe medications for sight-threatening conditions like eye infections and glaucoma.

7 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

ACADIA extends collaboration agreement with Allergan for drug discovery platform

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc.

1 Apr 2011